A Revised Approach for the Detection of Sight-Threatening Diabetic Macular Edema.

Macular DiseasesRetinal Diseases

Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE

Ophthalmology.

Reddy RK, Pieramici DJ, Gune S, Ghanekar A, Lu N, Quezada-Ruiz C, Baumal CR

doi: 10.1016/

Macular Diseases

Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial

JAMA Ophthalmol.

Glassman AR, Baker CW, Beaulieu WT, Bressler NM, Punjabi OS, Stockdale CR, Wykoff CC, Jampol LM, Sun JK, DRCR Retina Network

doi: 10.1001/jamaophthalmol.2019.6035.

Macular DiseasesRetinal Diseases

Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema: A Subanalysis of the RESTORE (Extension) Study

JAMA Ophthalmol.

Karst SG, Deak GG, Gerendas BS, Waldstein SM, Lammer J, Simader C, Guerin T, Schmidt-Erfurth UM

doi: 10.1001/jamaophthalmol.

Macular Diseases

Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success

Graefes Arch Clin Exp Ophthalmol.

Laiginhas R, Silva MI, Rosas V, Penas S, Fernandes VA, Rocha-Sousa A, Carneiro Â, Falcão-Reis F, Falcão MS

doi: 10.1007/s00417-017-3836-1.

Macular Diseases

Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial

JAMA Ophthalmol.

Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd; Diabetic Retinopathy Clinical Research Network

doi: 10.1001/

Macular DiseasesRetinal Diseases

Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study

Clin Ophthalmol.

Kulikov AN, Sosnovskii SV, Berezin RD, Maltsev DS, Oskanov DH, Gribanov NA

doi: 10.2147/OPTH.S146019.

Macular Diseases

AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes

Retina.

Bahrami B, Hong T, Schlub TE, Chang AA

doi: 10.1097/IAE.

COMMENTED

Macular Diseases

Anti-VEGF Treatment for Diabetic Macular Edema in a Real-World Clinical Setting

Am J Ophthalmol.

Maggio E, Sartore M, Attanasio M, Maraone G, Guerriero M, Polito A, Pertile G

doi: 10.1016/j.ajo.2018.08.004.

Retinal Diseases

Deep Learning Fundus Image Analysis for Diabetic Retinopathy and Macular Edema Grading

Sci Rep.

Sahlsten J, Jaskari J, Kivinen J, Turunen L, Jaanio E, Hietala K, Kaski K

doi: 10.1038/s41598-019-47181-w.

Related content

Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE

Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial

Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema: A Subanalysis of the RESTORE (Extension) Study

Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success

Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial

Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study

AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes

Anti-VEGF Treatment for Diabetic Macular Edema in a Real-World Clinical Setting

Deep Learning Fundus Image Analysis for Diabetic Retinopathy and Macular Edema Grading